Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN), Alexion Pharmaceuticals, Inc. (ALXN): Biotech’s Falling Fortunes Stymie Osiris Therapeutics, Inc. (OSIR)’s Huge Week

Page 1 of 2

Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts. The industry had a rough week as a whole, as the Nasdaq Biotechnology Index followed up on last week’s losses with an ugly 2.8% plunge this week. But in an industry like this, there are always big gainers and big losers every week – and this was no exception.

From buyout questions to the reception of strong clinical data, let’s check out what moved biotech over the past five days.

Buyout talk on hold

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) certainly didn’t help the index out this week, as shares of the big biotech lost almost 9% for the week. Buyout rumors have raged around Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) for some time now, and while those have helped the stock gain more than 20% over the past three months, the past month hasn’t been so kind for the firm: Onyx has lost nearly 13% over that span, particularly exacerbated by the past week.

Amgen, Inc. (NASDAQ:AMGN) was responsible for much of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)’s fall, as the company requested data from a trial of Onyx’s cancer drug Kyprolis before progressing with negotiations. Amgen, Inc. (NASDAQ:AMGN)’s been one of the names most closely tied to an Onyx buyout, and Kyprolis would fill in a big need for Amgen’s future sales. Analysts have pegged the  drug’s peak sales at $1.5 billion. Onyx fears that accessing the ongoing trial data could influence the trial itself, but some analysts are concerned that Amgen’s using the trial as leverage to wager a lower buy price out of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).

Still, a report from Reuters recently claimed that Amgen, Inc. (NASDAQ:AMGN) was closing in on a $9.5 billion offer for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), something that would boast a $1 billion premium over Onyx’s current market cap. Even a slight decrease would be a win for investors.

Buyout talk is swirling around orphan drug star Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) as well, but caution around the acquisition suggestions took Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)’s stock down almost 8% for the week. Big Pharma giant Roche (OTCBB:RHHBY) had been rumored to be looking for financing to acquire Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), but analysts have recently given the thumbs-down to the possibility after nebulous comments from Roche’s CEO.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) could use the boost, given that it’s up only around 5% year to date. For now, however, it looks like we’ll have to wait on whether Roche is gearing up for a costly buy.

Those are two big losers for the sector this week, but little Osiris Therapeutics, Inc. (NASDAQ:OSIR) kept biotech from an even worse week, as its stock catapulted higher by a ridiculous 86% over the past five days. Osiris Therapeutics, Inc. (NASDAQ:OSIR) won FDA approval for its Grafix stem cell wound treatment back in 2010, but the drug hit its primary endpoints in a recent clinical trial.

Grafix scored a big win in treating diabetic ulcers in the trial, and analysts are more optimistic that the data will help boost sales of the drug. Sixty-two percent of trial patients using the drug achieved a closure of wounds, more than triple the number who hit the mark in a control group.

Page 1 of 2
Loading Comments...